公开(公告)号：US10239953B2

公开(公告)日：2019-03-26

申请号：US15117027

申请日：2015-02-09

申请人： KATHOLIEKE UNIVERSITEIT LEUVEN ,  INSERM (Institut National de la Santé et de la Recherche Médicale) ,  Université de Caen Basse Normandie ,  Centre Hospitalier Universitaire de Caen

发明人： Paul Declerck ,  Simon De Meyer ,  Nick Geukens ,  Ann Gils ,  Marina Rubio ,  Denis Vivien ,  Tine Wyseure

IPC分类号： A61K39/395 ,  C07K16/38 ,  A61K39/00

摘要： Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).

公开(公告)号：US20210128701A1

公开(公告)日：2021-05-06

申请号：US16592554

申请日：2019-10-03

申请人： Baxalta Incorporated ,  Baxalta GmbH ,  Katholieke Universiteit Leuven

发明人： Barbara PLAIMAUER ,  Hanspeter Rottensteiner ,  Friedrich Scheiflinger ,  Simon De Meyer ,  Frederik Denorme

IPC分类号： A61K38/48 ,  A61P9/10

摘要： Provided herein are methods for recanalization of occluded blood vessels in a subject having an infarction. The method includes a step of administering to the subject a therapeutically effective amount of isolated ADAMTS13 protein at particular dosages and ranges of times after detection of the infarction. As described herein, ADAMTS13 advantageously recanalizes occluded blood vessels and reduces infarction size, even when administered a prolonged period after stable occlusion. Accordingly, such methods and compositions are useful for the treatment of infractions caused by blood vessel occlusion.